U.S. clears manufacturing ramp-up of Bavarian Nordic's monkeypox vaccine

The U.S. Food and Drug Administration on Wednesday approved Bavarian Nordic's plans to ramp up manufacturing of its Jynneos vaccine that is being used in efforts to stem a global outbreak of monkeypox.

After completing the inspection of a manufacturing plant earlier this month, the FDA has determined the vaccine made at the plant meets the agency's quality standards, it said in a tweet.